Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O60256

UPID:
KPRB_HUMAN

ALTERNATIVE NAMES:
41 kDa phosphoribosypyrophosphate synthetase-associated protein

ALTERNATIVE UPACC:
O60256; B4E1M8; B4E329; B7ZKZ1; E7EMY2; Q6IAS2

BACKGROUND:
The Phosphoribosyl pyrophosphate synthase-associated protein 2, alternatively named the 41 kDa phosphoribosypyrophosphate synthetase-associated protein, negatively regulates the synthesis of 5-phosphoribose 1-diphosphate. This activity is pivotal for maintaining the homeostasis of nucleotide pools within the cell, influencing both DNA and RNA synthesis processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Phosphoribosyl pyrophosphate synthase-associated protein 2 offers a promising avenue for the development of novel therapeutic approaches. Given its critical role in nucleotide synthesis, targeting this protein could lead to breakthroughs in treating conditions associated with nucleotide metabolism anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.